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Can Antihypertensive Treatment Restore the Risk of Cardiovascular
Disease to Ideal Levels?
The Coronary Artery Risk Development in Young Adults (CARDIA) Study and
the Multi-Ethnic Study of Atherosclerosis (MESA)
Kiang Liu, PhD; Laura A. Colangelo, MS; Martha L. Daviglus, MD, PhD; David C. Goff, MD, PhD; Mark Pletcher, MD, MPH;
Pamela J. Schreiner, PhD; Christopher T. Sibley, MD; Gregory L. Burke, MD, MSc; Wendy S. Post, MD, MS; Erin D. Michos, MD, MHS;
Donald M. Lloyd-Jones, MD, ScM
Background-—It is unclear whether antihypertensive treatment can restore cardiovascular disease risk to the risk level of persons
with ideal blood pressure (BP) levels.
Methods and Results-—Data from the Multi-Ethnic Study of Atherosclerosis (MESA) and the Coronary Artery Risk Development in
Young Adults (CARDIA) study were analyzed. Outcomes were compared among participants without or with antihypertensive
treatment at 3 BP levels: <120/<80 mm Hg, systolic BP 120 to 139 mm Hg or diastolic BP 80 to 89 mm Hg (120 to 129/
≤80 mm Hg for participants with diabetes), and systolic BP ≥140 or diastolic BP ≥90 mm Hg (systolic BP ≥130 or diastolic BP
≥80 mm Hg for participants with diabetes). Among MESA participants aged ≥50 years at baseline, those with BP <120/
<80 mm Hg on treatment had higher left ventricular mass index, prevalence of estimated glomerular filtration rate <60 mL/min
per 1.73 m2, prevalence of coronary calcium score >100, and twice the incident cardiovascular disease rate over 9.5 years of
follow-up than those with BP <120/<80 mm Hg without treatment. In CARDIA at year 25, persons with BP <120/<80 mm Hg
with treatment had much longer exposure to higher BP and higher risk of end-organ damage and subclinical atherosclerosis than
those with BP <120/<80 mm Hg without treatment. An exploratory analysis suggested that when cumulative systolic BP was high
(eg, >3000 mm Hg–years in 25 years), the increase in left ventricular mass index accelerated.
Conclusions-—The data suggest that based on the current approach, antihypertensive treatment cannot restore cardiovascular
disease risk to ideal levels. Emphasis should be placed on primordial prevention of BP increases to further reduce cardiovascular
disease morbidity and mortality. ( J Am Heart Assoc. 2015;4:e002275 doi: 10.1161/JAHA.115.002275)
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P rospective studies of cardiovascular disease (CVD) haveshown that baseline blood pressure (BP) levels measured
during young adulthood have a strong and direct association
with risk of long-term CVD events, despite potential changes
in BP at older ages.1–3 The Framingham Heart Study reported
that BP levels measured at baseline or in the remote past are
more predictive of CVD events than BP levels measured more
proximally to the event.4 Similarly, data from the Coronary
Artery Risk Development in Young Adults (CARDIA) study
suggest that higher BP levels within nonhypertensive ranges
at young ages are also strongly associated with subclinical
CVD many years later.5–7
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Despite the known association of BP levels with CVD events
extending well into optimal ranges,8 BP treatment guidelines
have focused on initiation of antihypertensive therapy only after
BP exceeds certain thresholds (eg, systolic BP [SBP]
≥140 mm Hg or diastolic BP [DBP] ≥90 mm Hg).9 It is firmly
established that use of antihypertensive medications to lower
BP for persons within this hypertensive range is associated with
substantially lower risks for cardiovascular outcomes, including
stroke, heart failure, and coronary heart disease (CHD).10–13
Observational studies, however, have shown that after adjust-
ment for CVD risk factors, patients receiving antihypertensive
medication still appear to have higher risk of CVD than those not
on antihypertensive medication at the same achieved BP
levels.14–17 It is widely assumed that antihypertensive treat-
ment to BP levels <120/<80 mm Hg cannot restore risk levels
to those of someone who always maintains such optimal BP
levels, but no direct empirical evidence has addressed this
point. Furthermore, no data have been shown to explain why
lowering BP to the ideal level with medication cannot restore
low risk. Existing randomized clinical trial data cannot answer
this question because studies have focused only on patients
with clinically elevated BP and on short-term outcomes.
Although it remains unclear why recent BP measures are
less predictive of CVD events than remote measures, an
explanation is that because BP tracks over time, higher BP
levels at young ages may be a surrogate for long-term
exposure to elevated BP levels. Similarly, BP levels obtained
later and closer to CVD events may have been altered by
recent changes or interventions and thus may not adequately
reflect cumulative damage to the myocardium and vascula-
ture. To date, this issue has not been clearly addressed. We
sought to determine whether effective treatment of hyper-
tension can lower the risk of CVD to that seen in those who
have always had ideal BP levels and to explore potential
mechanisms that may preclude the restoration of low-risk
status despite effective antihypertensive therapy.
Methods
Study Participants
The CARDIA study, sponsored by the National Heart, Lung, and
Blood Institute (NHLBI), is a multicenter longitudinal study
consisting of 5115 black and white women and men aged 18 to
30 years at the baseline examination (Y0) in 1985–1986 who
were free of CVD. Seven follow-up examinations took place at
years 2, 5, 7, 10, 15, 20 (Y20), and 25 (Y25). Participants in the
CARDIA cohort were excluded from the analysis if they did not
attend the Y25 examination (n=1617), were missing data on all
Y25 outcome measures (n=3), were missing Y25 BP measure-
ments (n=6), were missing data on Y25 covariates (n=231), or
developed CVD prior to Y25 (n=94). This left 3164 participants
in the primary analytic cohort. An additional person was
excluded from analyses involving left ventricular (LV) mass due
to an unlikely, large LV mass (502 g). Participants were
permitted to bemissing data on some but not all Y25 outcomes,
thus the sample sizes for different outcomes may be slightly
<3164 participants. For participants who attended the baseline
and Y25 examinations and at least 4 of 6 intermediate
examinations, 25-year cumulative SBP was computed. In the
analyses relating 25-year cumulative SBP to LV mass index
(LVMI) in untreated CARDIA participants (n=2362), 368 were
excluded due to missing LVMI (n=214) or missing 25-year
cumulative SBP (n=154) or had cumulative SBP outside of the
range 2200 to 3600 mm Hg–years (n=4), leaving 1990 partic-
ipants for that analysis (Figure 2). In the exploratory analysis in
Table 4, 236 participants (137 missing LVMI and 99 missing
cumulative SBP) were excluded from the 1669 participants with
BP <120/<80 at Y25, leaving 1433 participants. Because the
cohort is relatively young and only 2 years of CVD event follow-
up data were available after the Y25 examination, there were
too few CVD events for statistical analysis.
The Multi-Ethnic Study of Atherosclerosis (MESA) is also an
NHLBI-sponsored multicenter longitudinal study consisting of
6814 white (38%), black (28%), Hispanic (23%), and Chinese
(12%) women and men aged 45 to 84 years who were free of
CVD at baseline (2000–2002). Participants were excluded
from analysis if they had fasting time <8 hours (n=6); missing
SBP, low-density lipoprotein cholesterol, diabetes status, or
smoking status (n=121); missing antihypertensive medication
information (n=2); or prebaseline events (n=4). In addition,
because most younger people were in the normotensive group,
we excluded 883 participants aged <50 years at baseline to
enhance the age comparability between the BP treatment
groups. The total sample size for this analysis was 5798.
All participants in both studies signed informed consent,
and the studies were approved by the institutional review
board of each field center. Details regarding these 2 studies
have been published previously.18,19
CARDIA Data Collection
All measurements were obtained by centrally trained and
certified technicians. Participants were asked to fast for
12 hours and to refrain from smoking and from heavy physical
activity for 2 hours before each examination. Seated BP was
measured using a random zero sphygmomanometer for the
examinations from Y0 to year 15 and an Omron model
HEM907XL at Y20 and Y25 examinations. After a 5-minute rest
in a quiet room, BP was measured on the right arm at three 1-
minute intervals; the average of the second and third measure-
ments was used. A calibration study was conducted (n=800) to
convert Y20 and Y25 values to their Y0 equivalents. Total
cholesterol was measured enzymatically by the Northwest Lipid
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Laboratory, and low-density lipoprotein cholesterol was calcu-
lated using the Friedewald equation.20 Glucose was assayed
using hexokinase coupled to glucose-6 phosphate dehydroge-
nase. Diabetes was defined by fasting glucose ≥126 mg/dL, 2-
hour glucose ≥200 mg/dL, HbA1c ≥6.5%, or medication use.
Creatinine was measured in serum by the Roche enzymatic
method. The estimated glomerular filtration rate (eGFR) was
estimated using the Chronic Kidney Disease Epidemiology
Collaboration equation.21 For height and weight measurements,
the participants wore light clothing without shoes. Sex, race, and
smoking data were collected using self-administrated question-
naires. Participants were asked to bring their medications with
them to the clinic visits. At Y25, participants underwent 2-
dimensionally guided M-mode echocardiography; all studies
were read centrally at the Johns Hopkins University Echocardio-
graphy Reading Center. LVMI was calculated by dividing the LV
mass (in grams) by height (in m2.7). Coronary calcium (CAC)
levels were measured at Y25 using multidetector computed
tomography of the chest.22 Images were read centrally by the
Computed Tomography Reading Center at Wake Forest Univer-
sity. Agatston score was calculated.23
MESA Data Collection
All data were collected by centrally trained and certified
technicians. Three BP measurements, 1 minute apart, were
collected using a Dinamap Pro100 model BP monitor, and the
average value of the second and third measurements was
used. Sex, race, and smoking data were collected using self-
administrated questionnaires. Weight and height were mea-
sured using a standard protocol. Again, participants were
asked to bring in their medications.
Details regarding lipid measurements have been pub-
lished.24 Serum glucose was measured by the glucose-oxidase
method. The eGFR was based on cystatin C.25 Chest computed
tomography was performed using either cardiac gated electron-
beam or multidetector computed tomography scanners.22
Images were read centrally for CAC by the Los Angeles
Biomedical Research Institute at Harbor–UCLAMedical Center.
The average Agatston score was used in the analysis.23 LVmass
was obtained by cardiac magnetic resonance imaging. Images
were acquired by 1.5T magnetic resonance imaging scanners
using a protocol described by Natori et al.26 The readings were
performed centrally by the MESA Magnetic Resonance Imaging
Reading Center at Johns Hopkins Hospital. LVMI was calculated
using the Dubois formula for body surface area.27
CARDIA and MESA Event Follow-up and
Adjudication
In CARDIA, participants were contacted every year to inquire
about interim hospitalizations. For each self-reported event,
medical records were obtained and adjudicated by 2 members
of the morbidity and mortality committee. CVD events
comprised nonfatal myocardial infarction or stroke; hospital-
ization for angina pectoris, congestive heart failure (CHF), or
transient ischemic attack; revascularization for or angiograph-
ically or ultrasound-demonstrated obstruction of carotid
artery disease or peripheral arterial disease; fatal atheroscle-
rotic coronary heart disease, fatal stroke, fatal atherosclerotic
disease other than coronary or stroke, and fatal
nonatherosclerotic cardiac disease. In MESA, incident CVD
events were recorded over a mean follow-up of 9.5 years (SD
2.4 years). Every 9 to 12 months, participants were contacted
to inquire about interim hospital admissions, cardiovascular
outpatient diagnoses and procedures, and deaths. Again, for
each self-reported event, the medical and hospital records
were obtained and adjudicated by 2 members of the morbidity
and mortality committee. For this report, all CHD events were
classified as myocardial infarction, resuscitated cardiac
arrest, definite angina, probable angina (if followed by
revascularization), and CHD death. All CVD events included
all CHD events plus stroke, stroke death, other atheroscle-
rotic death, and other CVD death. CHF was classified as
definite, probable, or absent. Definite or probable CHF
required heart failure symptoms such as shortness of breath
or edema. In addition to symptoms, probable CHF required
CHF diagnosed by a physician and medical treatment for CHF.
Definite CHF required 1 criterion or more, such as pulmonary
edema or congestion by chest x-ray, ventricular dilation or
poor LV function by echocardiography or ventriculography, or
evidence of LV diastolic dysfunction.
Statistical Analysis
CARDIA participants were classified into 6 BP treatment
groups defined by whether they were treated or untreated
with antihypertensive medication at Y25 and the severity level
of BP at Y25 as categorized by the Seventh Report of the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure, or JNC 7: normal
(untreated BP <120/<80 mm Hg), treated and well controlled
(BP <120/<80 mm Hg), untreated prehypertension (SBP 120
to 139 mm Hg or DBP 80 to 89 mm Hg, or SBP 120 to 129
with DBP <80 mm Hg for participants with diabetes), treated
and controlled (BP in prehypertension ranges), untreated
hypertension (BP ≥140/≥90 mm Hg or BP ≥130/
≥80 mm Hg for participants with diabetes), and treated and
uncontrolled (BP in untreated hypertension ranges).9 Similar
categories were used to define BP strata for MESA partici-
pants at baseline. For CARDIA participants who attended the
baseline and Y25 examinations and at least 4 of 6 interme-
diate examinations at years 2, 5, 7, 10, 15, and Y20, the
cumulative SBP (in mm Hg–years) was calculated by summing
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the product of the average SBP and the time interval (in years)
between 2 consecutive examinations over the 25 years.
Analyses were conducted using SAS statistical software
(version 9.4; SAS Institute) and R software (R Foundation for
Statistical Computing). Cox regression was used to obtain
hazard ratios (HRs) for the 6 baseline BP groups for incident
CHD, CVD, heart failure, and stroke in MESA participants,
adjusting for the baseline covariates age, sex, race, body
mass index, smoking status, low-density lipoprotein choles-
terol, and cholesterol medication. In addition, we reran the
Cox regression models using the Eighth Report of the Joint
National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure (JNC 8) criteria28 due to
changes in the treatment criteria. Under the JNC 8 criteria, the
initiation of antihypertensive medication for those aged
>60 years is delayed until they have SBP >150 or DBP
>90 mm Hg. The proportional hazards assumption was
examined using the time interaction test and the supremum
test. All tests were insignificant except for the comparison of
incident CVD between the groups of people with BP <120/
<80 mm Hg without medication and prehypertension patients
without medication; this comparison was borderline signifi-
cant (P=0.07 and P=0.04 for the time interaction and
supremum tests, respectively). This comparison is not the
focus of the paper, and the HR was not statistically significant.
For CARDIA, a generalized estimating equation model was
used to obtain estimates of age-, sex-, and race-adjusted SBP
and DBP at the 8 examination visits (Figure 1). ANCOVA was
used to estimate the CARDIA Y25 covariate-adjusted preva-
lence and MESA baseline covariate-adjusted prevalence of
CAC score >100 and eGFR <60 mL/min per 1.73 m2 for the
6 groups, and multiple logistic regression was used to test
significance. ANCOVA was used to compare the Y25 covari-
ate-adjusted LVMI among 6 BP groups.
In addition, in CARDIA, a large number of participants were
excluded from the analytic sample due to missing Y25
examinations, cumulative SBP, or LVMI. We compared
baseline age, sex, race, body mass index, smoking status,
BP, low-density lipoprotein cholesterol, high-density lipopro-
tein cholesterol, fasting glucose, education, serum creatinine,
alcohol intake, and total physical activity between those who
were included in the sample and those who were excluded
from the sample. The variables that were significantly
different between the 2 groups were used to develop a
propensity equation for inclusion based on the logistic
regression model for each end-organ-damage variable (ie,
LVMI, CAC, and eGFR). The inverse propensity probability of
inclusion was used to perform the weighted regression
analysis as sensitivity analyses for findings in Table 3.
A generalized additive model was used to model the
nonlinear relation of LVMI with cumulative SBP, adjusting for
the Y25 covariates. In the analysis, the adjusted mean of LVMI
is a smooth function of the cumulative SBP with additive
structure. The function is estimated by a nonparametric spline
method. An exploratory analysis was also performed to
estimate the potential break point. Specifically, we fit a
special piecewise linear model, which assumes that LVMI is
linearly related to cumulative SBP, with the slope of the
regression line changing at an unknown cumulative SBP level.
In addition, the Davies test29 was performed to test the
existence of the changing point. The main statistical analysis
was conducted using the packages segmented and mgcv in
R.3.1.3 (R Foundation for Statistical Computing) (Figure 2).
Results
Study Sample
Baseline characteristics of MESA participants and baseline
and Y25 characteristics of CARDIA participants are presented
in Tables 1 and 2, respectively, stratified by BP and treatment
groups (at baseline for MESA and at Y25 for CARDIA). In
MESA, the group with untreated BP <120/<80 mm Hg
tended to be younger and leaner than the other groups
(Table 1). In CARDIA, the group with untreated BP <120/
<80 mm Hg at Y25 had a higher proportion of women and
white participants, a lower prevalence of current smoking, and
lower average body mass index at baseline and at Y25 than
the other groups (Table 2).
Incident CVD Events in MESA
Risk factor–adjusted HRs for 9.5-year incident CVD, CHD,
heart failure, and stroke are presented in Table 3 for the 6 BP
groups, using the original JNC 7 criteria and the JNC 8 criteria.
Under the JNC 7 criteria, MESA participants with treated and
well-controlled BP had HRs of 2.19 (P<0.01), 2.02 (P<0.01),
1.70 (P=0.09), and 2.56 (P=0.01) for CVD, CHD, heart failure,
and stroke, respectively, compared with those with untreated
BP <120/<80 mm Hg. For the other 4 groups, except for
CHD and stroke in the untreated prehypertensive group, the
HRs for incident CVD, CHD, and stroke were all significantly
higher than for the group with untreated BP <120/
<80 mm Hg.
Similarly, participants with treated and controlled hyper-
tension had significantly higher hazards for incident CVD,
CHD, and heart failure compared with untreated prehyper-
tensive participants. Moreover, HRs for incident CVD, CHD,
heart failure, and stroke were similar between participants
with treated but uncontrolled hypertension and untreated
hypertension.
When this analysis was rerun using JNC 8 criteria, the
results were similar, except that in the prehypertension group,
the HRs for CHD and stroke were also significantly higher
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than for the group with untreated BP <120/<80 mm Hg. In
addition, for the prehypertension group, based on the JNC 8
criteria, the HRs for CVD, CHD, heart failure, and stroke were
1.65, 1.45, 1.45, and 2.22, respectively; these HRs are all
higher than the corresponding HRs—1.42, 1.29, 1.41, and
1.76 for CVD, CHD, heart failure, and stroke, respectively—
for the prehypertension group based on the JNC 7 criteria
(Table 3).
Long-Term BP Levels in CARDIA
Figure 1A shows the average BP at Y0 and at years 2, 5, 7,
10, 15, Y20, and Y25 for normotensive participants in CARDIA
at Y25 (closed circles) and hypertensive participants with
treated and well-controlled BP at Y25 (open circles). At Y0, the
average BPs in all 6 groups were much lower than 120/
80 mm Hg. The average SBPs and DBPs of participants who
became hypertensive but had well-controlled BP with treat-
ment at Y25 were already much higher at Y0 than the average
SBPs and DBPs of normotensive participants. Participants
who became hypertensive over time had greater elevations in
BP, as expected, and then returned to ideal BP levels with
treatment by Y25. Similar BP patterns were also observed
between the Y25 prehypertension group and the treated and
controlled group (Figure 1B) and between the treated but
uncontrolled group and the untreated hypertension group
A
C
B
Figure 1. Age-, race-, and sex-adjusted BP over time by Y25 BP level and antihypertensive treatment
status. Mean BP for CARDIA participants at Y25: (A) BP <120/<80 mm Hg. (B) SBP 120 to 139 mm Hg or
DBP 80 to 89 mm Hg (or SBP 120 to 129 with DBP <80 mm Hg for people with diabetes), (C) BP ≥140/
≥90 mm Hg (or BP ≥130/≥80 mm Hg for people with diabetes). The number of participants in each group
is given in Table 2. BP indicates blood pressure; CARDIA, Coronary Artery Risk Development in Young
Adults; DBP, diastolic blood pressure; SBP, systolic blood pressure; Y25, year 25.
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(Figure 1C), although differences between the latter 2 groups
were not as large. These data suggest that even participants
on antihypertensive medication with well-controlled BP
(<120/<80 mm Hg at Y25) have generally experienced a
longer period (in our study, ≥25 years) of BP at much higher
levels than those of the normotensive group.
BP Levels and End-Organ Damage or Subclinical
Atherosclerosis
In both CARDIA participants at Y25 and MESA participants at
baseline with BP (treated or untreated) either <120/
<80 mm Hg or from 120/80 to 139/89 mm Hg, those on
antihypertensive treatment had significantly higher LVMI, a
significantly higher prevalence of eGFR <60 mL/min per
1.73 m2, and a significantly higher prevalence of CAC score
>100 than the corresponding group without treatment
(Table 4).
In CARDIA, those who were excluded from the analyses
tended to be younger, men, black, and current smokers, with
higher SBP, DBP, low-density lipoprotein cholesterol, fasting
glucose, alcohol intake, and creatinine and lower education at
baseline. These baseline characteristics were used to develop
a propensity equation for inclusion for each variable described
for end-organ damage. A sensitivity analysis was performed
using the inverse propensity probability as the weights in the
regression analyses. The results were similar to those in
Table 4, with no material change (data not shown).
Figure 2 demonstrates the relationship between cumula-
tive SBP over 25 years and LVMI in CARDIA. In general, LVMI
was higher with greater exposure to cumulative SBP, and
when cumulative SBP exposure was high, the increase in LVMI
accelerated. In the changing point analysis, the Davies test
was significant for the existence of a change point, confirming
that the association between cumulative SBP exposure and
LVMI is not constant (P=0.04). The estimator of the change
point in the piecewise linear regression was 2885 mm Hg–
years. The slopes estimated before and after the break point
of 2885 mm Hg–years were 0.5 and 1.4 g/m2.7 per
100 mm Hg–years, respectively. Because stroke and tran-
sient ischemic attack are strongly associated with high BP
and are unlikely to affect LV mass directly, the results may be
overly conservative with the exclusion of these diseases. In a
sensitivity analysis, we reran the change point analysis
excluding CVD, except for stroke and transient ischemic
attack, prior to Y25. The change point in this case was
estimated at 2982 mm Hg–years with slopes before and after
this point of 0.5 and 2.1 g/m2.7 per 100 mm Hg–years,
respectively. The Davies test showed P=0.002.
The CARDIA data also allowed an exploratory examination
of whether early detection of hypertension and controlling BP
to <120/<80 mm Hg could prevent increasing end-organ
damage. The group of CARDIA participants with treated BP
<120/<80 mm Hg at Y25 was further classified into 2
subgroups. Group 2 included those who initiated treatment by
year 15, Y20, or Y25 with cumulative SBP <3000 mm Hg–
years and BP <120/<80 mm Hg in subsequent years through
Y25; group 3 included those who initiated treatment by year
15 or Y20 but were not always well controlled until Y25 or
those who had a cumulative SBP ≥3000 mm Hg–years. Group
1 consisted of normotensive participants at Y25. The adjusted
average LVMIs, prevalence of CAC score >100, and preva-
lence of eGFR <60 mL/min per 1.73 m2 of group 2 were all
lower (significantly or borderline significantly) than those of
group 3 even though they were higher (not statistically
significant) than those of group 1 (Table 5).
Discussion
The results of this study demonstrate that in MESA partic-
ipants aged ≥50 years at baseline, those with well-controlled
hypertension (<120/<80 mm Hg) on antihypertensive med-
2200 2400 2600 2800 3000 3200 3400 3600
30
35
40
45
50
55
Untreated CARDIA Participants 
Cumulative (mm Hg−year)
LV
M
I (g
/m
2.
7 )
Figure 2. Adjusted relationship by spline regression between
LVMI and 25-year cumulative systolic blood pressure in untreated
CARDIA participants (n=1990). Spline (solid line) with 95% point-
wise confidence band (dotted lines) is adjusted for year 25 age, sex,
race, body mass index, smoking status, diabetes, low-density
lipoprotein cholesterol, and cholesterol medication. The slopes at
the break point of 2885 cumulative mm Hg–years were estimated
to be 0.5 g/m2.7 per 100 mm Hg–years (95% CI 0.2 to 0.8) before
2885 mm Hg–years and after 2885 mm Hg–years is 1.4 g/m2.7
per 100 mm Hg–years (95% CI 0.7 to 2.1). CARDIA indicates
Coronary Artery Risk Development in Young Adults; LVMI, left
ventricular mass index.
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ication still had twice the risk of incident CVD events in the
next 9.5 years than participants with ideal BP levels without
treatment. The CARDIA results indicate that middle-aged
adults with well-controlled BP on medication had longer
exposure to higher BP levels than adults with ideal BP without
medication and had significantly higher risk of end-organ
damage, as measured by LVMI, renal function, and subclinical
atherosclerosis. We observed these findings even in CARDIA
participants who had mean BP levels below the typical
threshold for diagnosing hypertension. In addition, our
exploratory analysis suggested empirically that when cumu-
lative SBP was high, the increase in LVMI accelerated.
Previous studies have shown that higher BP levels, even
those not considered clinically high, at younger ages are
strongly associated with clinical and subclinical CVD.1–3,6,7
Results from the Framingham Heart Study showed BP levels in
the remote past as more predictive of incident CVD than more
recent BP levels.4 Loria et al reported that BP levels in young
adulthood (ages 18 to 30 years) were significantly associated
with coronary calcium 15 years later and that this association
Table 1. Baseline (2000–2002) Characteristics of MESA Participants Aged ≥50 Years Stratified by Baseline BP Level and
Antihypertensive Treatment Status
BP <120/<80 mm Hg at Baseline
SBP 120 to 139 or DBP 80 to 89 mm Hg
(or 120 to 129/<80 mm Hg for
Participants With Diabetes) at Baseline
SBP ≥140 or DBP ≥90 mm Hg (or ≥130
or ≥80 for Participants With Diabetes) at
Baseline
Untreated Treated to This Level Untreated Treated to This Level Untreated Treated to This level
n 1621 588 1069 740 757 1023
Age, y 60.6 (8.2) 65.1 (8.9) 63.7 (8.9) 65.9 (8.6) 66.8 (8.9) 68.2 (8.3)
Men, n (%) 736 (45.4) 287 (48.8) 569 (53.2) 358 (48.4) 359 (47.4) 424 (41.5)
Race, n (%)
White 742 (45.8) 265 (45.1) 441 (41.3) 270 (36.5) 273 (36.1) 266 (26.0)
Black 288 (17.8) 183 (31.1) 252 (23.6) 278 (37.6) 206 (27.2) 419 (41.0)
Hispanic 354 (21.8) 98 (16.7) 246 (23.0) 120 (16.2) 178 (23.5) 233 (22.8)
Chinese 237 (14.6) 42 (7.1) 130 (12.2) 72 (9.7) 100 (13.2) 105 (10.3)
BMI, kg/m2 26.6 (4.9) 29.5 (5.8) 28.1 (4.9) 29.4 (5.1) 28.2 (5.3) 29.7 (5.8)
Current smoker, n (%) 226 (13.9) 64 (10.9) 147 (13.8) 69 (9.3) 81 (10.7) 96 (9.4)
Values shown are mean (SD) or n (%). BMI indicates body mass index; BP, blood pressure; DBP, diastolic blood pressure; MESA, Multi-Ethnic Study of Atherosclerosis; SBP, systolic blood
pressure.
Table 2. Baseline (1985–1986) and Y25 Characteristics of CARDIA Participants Stratified by Y25 BP Level and Antihypertensive
Treatment Status
BP <120/<80 mm Hg at Y25
SBP 120 to 139 or DBP 80 to
89 mm Hg (or 120 to 129/<80 mm Hg
for Participants With Diabetes) at Y25
SBP ≥140 or DBP ≥90 mm Hg (or ≥130
or ≥80 for Participants With Diabetes)
at Y25
Untreated Treated to This Level Untreated Treated to This Level Untreated Treated to This Level
n 1334 335 802 264 227 202
Baseline age, y 24.8 (3.7) 25.6 (3.6) 24.9 (3.5) 25.6 (3.4) 24.9 (3.5) 25.9 (3.5)
Y25 age (y) 49.9 (3.7) 50.6 (3.6) 50.1 (3.5) 50.6 (3.5) 50.1 (3.5) 50.9 (3.6)
Men, n (%) 455 (34.1) 124 (37.0) 467 (58.2) 118 (44.7) 102 (44.9) 87 (43.1)
Black, n (%) 411 (30.8) 189 (56.4) 368 (45.9) 177 (67.1) 145 (63.9) 164 (81.2)
Baseline BMI, kg/m2 23.1 (3.9) 26.0 (6.0) 24.1 (4.1) 25.9 (5.5) 25.4 (5.0) 28.0 (6.1)
Y25 BMI, kg/m2 27.7 (6.0) 33.1 (8.2) 29.4 (5.9) 33.1 (7.7) 32.6 (7.3) 36.1 (8.7)
Baseline current smoker, n (%) 309 (23.3) 108 (32.4) 198 (24.8) 64 (24.5) 62 (27.4) 65 (32.2)
Y25 current smoker, n (%) 171 (12.8) 64 (19.1) 137 (17.1) 44 (16.7) 52 (22.9) 39 (19.3)
Values shown are mean (SD) or n (%). BMI indicates body mass index; BP, blood pressure; CARDIA, Coronary Artery Risk Development in Young Adults; DBP, diastolic blood pressure; SBP,
systolic blood pressure; Y25, year 25.
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was much stronger than the association with concurrent BP
levels.6 Pletcher et al reported that prehypertension during
young adulthood was strongly associated with coronary
calcium many years later.7 In addition, the Framingham Heart
Study, Atherosclerosis Risk in Communities (ARIC), and the
Cardiovascular Health Study (CHS) all demonstrated that for
Table 4. Adjusted* Measures of End-Organ Damage Stratified by Y25 BP Level (CARDIA) or Baseline BP Level (MESA) and
Antihypertensive Treatment Status
CARDIA Y25 (n=3164)
BP <120/<80 mm Hg at Y25
SBP 120 to 139 or DBP 80 to
89 mm Hg (or 120 to 129/
<80 mm Hg for Participants With
Diabetes) at Y25
SBP ≥140 or DBP ≥90 mm Hg (or
≥130 or ≥80 for Participants With
Diabetes) at Y25
Untreated Treated to This Level Untreated Treated to This Level Untreated Treated to This Level
Echo LVMI*, g/m2.7, mean (SEM) (n=2836) 37.9 (0.3) 39.9 (0.6)† 39.2 (0.4)† 42.2 (0.6)†‡ 43.0 (0.7)† 43.9 (0.8)†
CAC >100*§, prevalence, % (n=2890) 5.3 10.7† 7.9† 14.8†‡ 9.9† 12.7†
eGFR <60*§ (creatinine), prevalence, % (n=3160) 0.8 3.9† 0.6 2.1‡ 1.4 6.3†‡
MESA Age ≥50 at Baseline (n=5802)
BP <120/<80 mm Hg at Baseline
SBP 120 to 139 or Diastolic BP 80 to
89 mm Hg (or 120 to 129/
<80 mm Hg for Participants With
Diabetes) at Baseline
SBP ≥140 or Diastolic BP
≥90 mm Hg (or ≥130 or ≥80 for
Participants With Diabetes) at
Baseline
Untreated Treated to This Level Untreated Treated to This Level Untreated Treated to This Level
MRI LVMI*, g/m2, mean (SEM) (n=4220) 34.4 (0.2) 36.1 (0.3)† 35.8 (0.2)† 36.9 (0.3)†‡ 38.5 (0.3)† 39.8 (0.3)†‡
CAC >100*§, prevalence, % (n=5798) 21.9 28.5† 23.3 28.2†‡ 28.1† 32.4†‡
eGFR <60*§ (cystatin C), prevalence, % (n=5764) 4.7 10.0† 3.3 6.9†‡ 3.6 10.2†‡
BP indicates blood pressure; CAC, coronary calcium; CARDIA, Coronary Artery Risk Development in Young Adults; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate;
LVMI, left ventricular mass index; MESA, Multi-Ethnic Study of Atherosclerosis; MRI, magnetic resonance imaging; SBP, systolic blood pressure; Y25, year 25.
*Adjusted for age, sex, race, body mass index, smoking status, diabetes, low-density lipoprotein cholesterol, and cholesterol medication.
†P<0.01 for comparison with the untreated BP <120/<80 mm Hg group.
‡P<0.05 for pairwise comparison within BP stratum.
§ANCOVA was used to estimate the prevalence rates in the 6 groups, adjusting for the covariates measured at Y25 for CARDIA and at baseline for MESA; multiple logistic regression was
used to test for the significant differences between groups.
Table 5. BP Treatment Status, Cumulative SBP, and Adjusted* Measures of End-Organ Damage in People With BP <120/
80 mm Hg at Y25, CARDIA
Group
1 2 3
No Treatment, Never
Had BP ≥120/≥80 mm Hg
Initiated Treatment
at Y15, Y20, or Y25
and Well Controlled
at All Treated Visits
With Cumulative
SBP <3000 mm
Hg–Years
Initiated Treatment
and Well Controlled at
Y25 But With Cumulative
SBP ≥3000 mm Hg–Years
OR Initiated Treatment Prior
To or at Y20 But Not Well
Controlled Before Y25
n 1159 152 122
Cumulative SBP, mm Hg–years, unadjusted mean (SD) 2597 (159) 2759 (124) 3018 (190)
Echo LVMI*, g/m2.7, mean (SEM) 36.7 (0.2) 37.8 (0.7) 39.7 (0.8)‡‖
CAC >100*†, prevalence, % 4.2 5.4 17.9‡§
eGFR <60*† (creatinine), prevalence, % 0.9 2.1 6.9‡§
BP, blood pressure; CAC, coronary calcium; CARDIA, Coronary Artery Risk Development in Young Adults; eGFR, estimated glomerular filtration rate; LVMI, left ventricular mass index; SBP,
systolic blood pressure; Y, year.
*Adjusted for age, race, sex, diabetes, low-density lipoprotein cholesterol, cholesterol medication, body mass index, and smoking status measured at Y25.
†ANCOVA was used to estimate the prevalence rates in the 3 groups, adjusting for the Y25 covariates; multiple logistic regression was used to test for the significant differences between
groups.
‡P<0.001 compared with group 1.
§P<0.05 compared with group 2.
‖P=0.06 compared with group 2.
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the same BP levels, those on antihypertensive medication had
higher risk of incident CVD and mortality.14–17 The results are
echoed in more recent broad-based risk prediction equations
that include antihypertensive therapy as a covariate with a
positive coefficient.30,31 In this study, we further demon-
strated that even people with well-controlled BP (to <120/
<80 mm Hg) on antihypertensive medication—although BP
was assessed at 1 point in time—may have a risk of incident
CVD double that of people who have never had high BP.
These results do not suggest that antihypertensive therapy
is ineffective for CVD risk reduction. Our observational study
was not designed to answer this question. An immense array
of clinical trial data has established unequivocally that
lowering BP with antihypertensive medications lowers the
risk of incident CVD in middle-aged and older adults,
particularly heart failure and stroke in patients with hyper-
tension.10–13,32 Results from the Losartan Intervention for
Endpoint Reduction trial also suggest the regression of the
electrocardiographic evidence of hypertrophy on treatment.33
Our data, however, indicate that based on the current
approach for treating hypertension, the restoration of BP
levels ≤120/80 mm Hg with antihypertensive medication
may not fully restore the low risk of persons maintaining
these ideal BP levels consistently without medication. It is
unclear whether earlier treatment to maintain similar cumu-
lative exposure to BP would abolish this excess CVD risk. This
study indicates that for participants with similar BP levels,
those on antihypertensive treatment have much higher
cumulative BP exposure over time than those not treated.
Consequently, many have developed end-organ damage that
treatment may not completely reverse. Several large-scale
epidemiological studies indicate that CVD risk increases as BP
increases, even within the normal BP range,8,32 thus the
assumption that long-term exposure to higher BP levels may
lead to end-organ damage is reasonable. To our knowledge,
this study is the first that provides direct evidence to support
this theory and to explain why, in observational studies and at
the same BP levels, people on antihypertensive treatment
have a higher risk of incident CVD than people not on
treatment. In addition, the exploratory analysis of the
relationship between cumulative SBP and LVMI suggests that
when cumulative SBP is high (eg, >3000 mm Hg–years),
despite good control of BP with antihypertensive medication,
LVMI remains significantly higher than it does in people with
normal BP without treatment. The cumulative SBP of
3000 mm Hg–years is not very high. If, for example, a
person’s SBP increases evenly from 110 to 140 mm Hg over
25 years, that person’s cumulative SBP is 3125 mm Hg. This
finding suggests that there may be a “point of no return” for
BP, that is, after reaching high levels, damage to an end organ
may be difficult to reverse to the levels of those who never
had hypertension.
The results of this study also raise a question about recent
BP treatment recommendations to delay the initiation of
antihypertensive medication for those aged >60 years until
they exceed SBP of 150 or DBP of 90 mm Hg.28 The higher
HRs for CVD, CHD, heart failure, and stroke in the prehyper-
tension group based on JNC 8 criteria compared with the
corresponding HRs in prehypertension groups based on JNC 7
criteria suggest that postponing treatment from 140 to
150 mm Hg in people aged ≥60 years may increase the risk
of incident CVD events. This delay in treatment will also
increase cumulative BP exposure and thus may increase end-
organ damage and the risk of reaching the point of no return,
if it exists.
Results from the Trial of Preventing Hypertension (TRO-
PHY) study suggest that reductions in incident hypertension
and lower overall cumulative exposure to BP levels can be
achieved with pharmacological therapy in those with prehy-
pertensive BP levels.34 An even more desirable approach
would be effective implementation of social, public health, and
medical care policies to promote maintenance of ideal BP
levels from youth into older age and to help restore ideal BP in
people on antihypertensive medication through healthier diets
and lifestyle modifications.
In the CARDIA study, a large number of participants were
excluded due to nonparticipation in the Y25 examination and
missing LVMI or cumulative SBP. The large missing values
may create biases in the results. We compared those who
were included in the analysis and those who were excluded
from the analysis with respect to the baseline characteristics.
We then developed a propensity equation for inclusion based
on the characteristics that were significantly different
between the 2 groups. For each end-organ-damage variable,
we used the inverse propensity probability for inclusion to
perform the weighed regression analyses. The results are
very similar, thus the CARDIA findings are unlikely to be
biased.
These data from the CARDIA and MESA studies provide a
unique opportunity to examine whether BP treatment can
lower CVD risk to ideal levels; however, the findings are from
observational studies, not randomized controlled clinical
trials, and take into account neither the potential adverse
effects of antihypertensive medications nor their financial
costs. In addition, because the BP measurements were taken
at a single visit, there may be some misclassification due to
day-to-day variability. Consequently, the results should be
interpreted with caution. Nonetheless, among all 6 BP strata
in both studies, the normotensive group showed the lowest
risk of end-organ damage and clinical CVD. These results
clearly indicate that, from a public health standpoint, health
care providers should place more emphasis on primordial
prevention of BP elevation to further reduce CVD morbidity
and mortality.
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